RVPH (Reviva Pharmaceuticals Holdings) Moat Score: 3/10 (As of Jul. 03, 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
26 GF Score
Price $0.66
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Moat Score?

Reviva Pharmaceuticals Holdings RVPH +0.36% 26 Moat Score is 3 as of Jul. 03, 2026. GuruFocus rates RVPH with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,399 Biotechnology companies, Reviva Pharmaceuticals Holdings ranks better than 75.48% on this metric.

Reviva Pharmaceuticals Holdings has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Reviva Pharmaceuticals Holdings has No Moat: Reviva Pharmaceuticals Holdings Inc operates in a competitive pharmaceutical industry with limited market leadership and intellectual property. It lacks significant regulatory barriers and customer loyalty, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Reviva Pharmaceuticals Holdings might have No Moat - Very weak/transient advantages.

Reviva Pharmaceuticals Holdings  (OTCPK:RVPH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Reviva Pharmaceuticals Holdings Moat Score Related Terms

RVPH vs AIM, BOLT, BRTX: Moat Score Comparison

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Moat Score falls into.


RVPH
26GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Moat Score of 3 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #343 out of 1399 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Reviva Pharmaceuticals Holdings' Moat Score too high?
Reviva Pharmaceuticals Holdings' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Reviva Pharmaceuticals Holdings' value of 3 is 50% above this industry median. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #343 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Moat Score compare to AIM and BOLT?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #343 out of 1399 companies for Moat Score. This places Reviva Pharmaceuticals Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Reviva Pharmaceuticals Holdings' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reviva Pharmaceuticals Holdings's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reviva Pharmaceuticals Holdings's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Reviva Pharmaceuticals Holdings' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Moat Score is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
26GF Score

Get the complete analysis for RVPH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price